Meletios Dimopoulos on relapsed and refractory multiple myeloma

<p>Professor Meletios Dimopoulos joins us to discuss two trials for patients with relapsed and refractory multiple myeloma - the first report of the DREAMM-3 phase 3 and long-term follow-up of the APOLLO phase 3 trial.<br/><br/>Read the full article:<br/><a href='https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(23)00243-0/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanhae'>https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(23)00243-0/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanhae</a></p><p>Continue this conversation on social!<br/>Follow us today at...<br/><a href='https://twitter.com/thelancet'>https://twitter.com/thelancet</a><br/><a href='https://instagram.com/thelancetgroup'>https://instagram.com/thelancetgroup</a><br/><a href='https://facebook.com/thelancetmedicaljournal'>https://facebook.com/thelancetmedicaljournal</a><br/><a href='https://linkedin.com/company/the-lancet'>https://linkedIn.com/company/the-lancet</a><br/><a href='https://www.youtube.com/thelancettv'>https://youtube.com/thelancettv</a></p>